<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573309</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1840-WD-204</org_study_id>
    <secondary_id>2020-001104-41</secondary_id>
    <nct_id>NCT04573309</nct_id>
  </id_info>
  <brief_title>Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840</brief_title>
  <official_title>A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study will investigate the effects of ALXN1840 on copper balance in&#xD;
      participants with Wilson disease (WD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who are treatment experienced (which includes standard-of-care therapies or&#xD;
      ALXN1840) and treatment naïve are eligible for this study.&#xD;
&#xD;
      Safety will be monitored throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Daily Copper Balance</measure>
    <time_frame>Accumulation: Day 1 through Day 8 (ALXN1840 15 mg) and Day 31 through Day 35 (ALXN1840 30 mg); Steady state: Day 25 through Day 28 (ALXN1840 15 mg) and Day 36 through Day 39 (ALXN1840 30 mg)</time_frame>
    <description>Copper balance is defined as the difference between the measured copper input in food and drink, and the measured copper elimination in urine and feces, and will be calculated as the average daily copper balance over the collection period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Mean Daily Copper Balance</measure>
    <time_frame>Accumulation: Baseline, Day 1 through Day 8 (ALXN1840 15 mg) and Day 31 through Day 35 (ALXN1840 30 mg); Steady State: Baseline, Day 25 through Day 28 (ALXN1840 15 mg) and Day 31 through Day 39 (ALXN1840 30 mg)</time_frame>
    <description>Copper balance is defined as the difference between the measured copper input in food and drink, and the measured copper elimination in urine and feces, and will be calculated as the average daily copper balance over the collection period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Copper Quantified In Food, Drink, Feces, And Urine, Including Plasma Total And Labile Bound copper (LBC)</measure>
    <time_frame>Accumulation: Day 1 through Day 8 for 15 mg and Day 31 through Day 35 for 30 mg; Steady state: Day 25 through Day 28 for ALXN1840 15 mg and Day 36 through Day 39 for ALXN1840 30 mg</time_frame>
    <description>Copper will be assessed through measurement of copper intake (in food and drink), and copper output (in feces and urine) as well as plasma total and labile bound copper.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molybdenum Specified In ALXN1840 Doses Given And Quantified In Food, Drink, Feces, And Urine, Including Plasma At Steady State</measure>
    <time_frame>Day 25 through Day 28 (ALXN1840 15 mg) and Day 36 through Day 39 (ALXN1840 30 mg)</time_frame>
    <description>Molybdenum balance is defined as the difference between the measured molybdenum intake (in food, drink, and ALXN1840), and molybdenum output (in feces and urine), and will be calculated as the average daily molybdenum balance over the collection period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Total Molybdenum Excretion In Urine And Feces</measure>
    <time_frame>Accumulation: Baseline, Day 1 through Day 8 (ALXN1840 15 mg) and Day 31 through Day 35 (ALXN1840 30 mg); Steady State: Baseline, Day 25 through Day 28 (ALXN1840 15 mg) and Day 36 through Day 39 (ALXN1840 30 mg)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Molybdenum Balance At Steady State</measure>
    <time_frame>Steady state: Day 25 through Day 28 (ALXN1840 15 mg) and Day 36 through Day 39 (ALXN1840 30 mg)</time_frame>
    <description>Molybdenum balance at steady state will be assessed through measurement of molybdenum intake (in food, drink, and ALXN1840), and molybdenum output (in feces and urine). Steady state is defined as molybdenum(out) equal to molybdenum(in).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Of Molybdenum As Determined By Molybdenum Balance</measure>
    <time_frame>Accumulation: Day 1 through Day 8 for 15 mg and Day 31 through Day 35 for 30 mg</time_frame>
    <description>Molybdenum balance will be assessed through measurement of molybdenum intake (in food, drink, and ALXN1840), and molybdenum output (in feces and urine).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Wilson Disease</condition>
  <arm_group>
    <arm_group_label>ALXN1840</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered ALXN1840 at a dose of 15 milligrams (mg)/day on Day 1 through Day 28 and then increased to 30 mg/day on Day 29 through Day 39</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1840</intervention_name>
    <description>Administered orally as tablets.</description>
    <arm_group_label>ALXN1840</arm_group_label>
    <other_name>formerly WTX101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of WD by Leipzig Criteria &gt; 4.&#xD;
&#xD;
          2. Able to reside in the clinical research unit for intensive metabolic monitoring of&#xD;
             copper and molybdenum.&#xD;
&#xD;
          3. Participants willing to adhere to copper/molybdenum-controlled diet during the study.&#xD;
&#xD;
          4. Willing and able to follow protocol-specified contraception requirements.&#xD;
&#xD;
          5. Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated cirrhosis or model for end stage liver disease score &gt; 13.&#xD;
&#xD;
          2. Modified Nazer score &gt; 7.&#xD;
&#xD;
          3. Clinically significant gastrointestinal bleed within past 3 months.&#xD;
&#xD;
          4. Alanine aminotransferase &gt; 2 × upper limit of normal.&#xD;
&#xD;
          5. Hemoglobin less than lower limit of the reference range for age and sex.&#xD;
&#xD;
          6. Significant medical history (current or past).&#xD;
&#xD;
          7. Previous treatment with zinc within 30 days prior to the Screening Visit.&#xD;
&#xD;
          8. Participants in renal failure, defined as in end-stage renal disease on dialysis&#xD;
             (chronic kidney disease stage 5) or creatinine clearance &lt; 30 milliliters/minute.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals Inc.</last_name>
    <phone>855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Copper Balance</keyword>
  <keyword>Molybdenum Balance</keyword>
  <keyword>Wilson Disease</keyword>
  <keyword>ALXN1840</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatolenticular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

